Cargando…

Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial

Detalles Bibliográficos
Autores principales:	Porta, Camillo, Ganini, Carlo, Paglino, Chiara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2012
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708205/ https://www.ncbi.nlm.nih.gov/pubmed/26816698 http://dx.doi.org/10.3978/j.issn.2223-4683.2012.05.07

Ejemplares similares

Immunological Effects of Multikinase Inhibitors for Kidney Cancer: A Clue for Integration with Cellular Therapies?
por: Porta, Camillo, et al.
Publicado: (2011)

Sunitinib re-challenge in advanced renal-cell carcinoma
por: Porta, C, et al.
Publicado: (2014)

Cytokine-Based Immunotherapy for Advanced Kidney Cancer: Past Results and Future Perspectives in the Era of Molecularly Targeted Agents
por: Porta, Camillo, et al.
Publicado: (2007)

Lingual metastasis from renal cell carcinoma: a case report and literature review
por: Ganini, Carlo, et al.
Publicado: (2012)

The complexity of sunitinib dosing in renal cell cancer patients
por: Desar, Ingrid M.E., et al.
Publicado: (2012)

Results of weekday-on and weekend-off administration schedule of sunitinib therapy for advanced renal cell carcinoma
por: Kawashima, Atsunari, et al.
Publicado: (2018)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance
por: Lin, Harrison Sicheng, et al.
Publicado: (2022)

Predicting responses to sunitinib using single nucleotide polymorphisms: Progress and recommendations for future trials
por: Ganapathi, Ram N, et al.
Publicado: (2011)

Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib
por: Beltran, Himisha, et al.
Publicado: (2014)

Shortening Tuberculosis treatment schedules in children
por: Barnes, Katharine
Publicado: (2022)

Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma
por: Porta, Camillo, et al.
Publicado: (2008)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Ordu, Çetin, et al.
Publicado: (2016)

Sunitinib for advanced renal cell cancer
por: Coppin, Chris
Publicado: (2008)

Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule
por: Di Paolo, Antonello, et al.
Publicado: (2017)

Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial
por: Cella, David, et al.
Publicado: (2014)

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor
por: Khosravan, Reza, et al.
Publicado: (2016)

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors
por: Okamoto, Isamu, et al.
Publicado: (2010)

Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy
por: Porta, Camillo, et al.
Publicado: (2011)

Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma
por: Zhu, Xudong, et al.
Publicado: (2021)

Granulation of m(1)A-modified mRNAs protects their functionality through cellular stress
por: Jiang, Hao
Publicado: (2020)

What a Clinician Should Know About a Renal Replacement Membrane?
por: Honore, Patrick M., et al.
Publicado: (2018)

Advances in Liver Transplantation: where are we in the pursuit of transplantation tolerance?
por: Safinia, Niloufar, et al.
Publicado: (2021)

Kidney injury molecule-1: a novel entry factor for SARS-CoV-2
por: Wan, Cheng, et al.
Publicado: (2021)

Measuring single‐cell protein secretion in immunology: Technologies, advances, and applications
por: Bucheli, Olivia T. M., et al.
Publicado: (2021)

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
por: Gore, M E, et al.
Publicado: (2015)

Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer?
por: Gross-Goupil, Marine, et al.
Publicado: (2012)

Margetuximab: An active alternative for later‐line therapy in patients with HER2‐positive advanced breast cancer
por: Zhou, Yunxiang, et al.
Publicado: (2023)

Type I interferon signaling deficiency results in dysregulated innate immune responses to SARS‐CoV‐2 in mice
por: Ogger, Patricia P., et al.
Publicado: (2022)

Second-line sunitinib for Chinese patients with advanced gastrointestinal stromal tumor: 37.5 mg schedule outperformed 50 mg schedule in adherence and prognosis
por: Zhang, Chenli, et al.
Publicado: (2021)

JUPITER‐02 trial: advancing survival for recurrent metastatic nasopharyngeal carcinoma and next steps
por: Tan, Laura Ling Ying, et al.
Publicado: (2021)

Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study
por: Buti, Sebastiano, et al.
Publicado: (2017)

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
por: Rovithi, Maria, et al.
Publicado: (2016)

Tolerability of Alternative Dosing Schedules for Sunitinib: A Systematic Review and Meta-Analysis
por: Kang, Hee Jung, et al.
Publicado: (2020)

Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma
por: Geynisman, Daniel M., et al.
Publicado: (2022)

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
por: Grünwald, Viktor, et al.
Publicado: (2023)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2022)

Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vhvidumpm3prh2sjivo3aqdikc